The Global Acute Repetitive Seizures Market Is Driven By Rising...

The Global Acute Repetitive Seizures Market Is Driven By Rising Incidence Of Epilepsy

Postado 2024-05-16 06:53:40

891

The global acute repetitive seizures market covers products that are used for management of acute repetitive seizures arising due to conditions like epilepsy. Acute repetitive seizures occur when a person experiences two or more seizures without regaining consciousness between seizures and can be potentially life-threatening if not treated promptly. Drugs that help terminate acute repetitive seizures include benzodiazepines that work by enhancing the brain inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Nasal sprays and intravenous injections are among the preferred forms of delivery of these drugs owing to the convenience of rapid administration during emergencies.

The Global Acute Repetitive Seizures Market is estimated to be valued at US$ 7.12 Bn in 2024 and is expected to exhibit a CAGR of 12.% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the acute repetitive seizures market are Neurelis, Inc., Bausch Health Companies Inc., Alexza Pharmaceuticals, Inc., VERITON PHARMA, UCB S.A., Takeda Pharmaceutical Company Limited, Pfizer Inc., Sanofi, GSK plc, Eisai Co., Ltd., H. Lundbeck A/S, Cognizance Biomarkers, LLC. Key players are focused on developing novel drug delivery formulations for rapid termination of seizures through nasal spray and intravenous routes.

The Acute Repetitive Seizures Market Growth is driven by the growing incidence of epilepsy worldwide. According to the World Health Organization, around 50 million people suffer from epilepsy globally. The risk of acute repetitive seizures is high among patients with uncontrolled or refractory epilepsy. Growing patient awareness and frequent launches of advanced treatment therapies are fueling the demand for acute repetitive seizures management.

The market is also witnessing expansion in emerging economies due to increasing healthcare expenditures. Support from government initiatives for epilepsy care and rising discretionary incomes are expected to boost the uptake of acute repetitive seizures drugs across developing regions in the coming years.

Market Drivers

The increasing R&D investments by players for developing innovative drug delivery systems is a major factor augmenting the acute repetitive seizures market growth. Several pharmaceutical companies are engaged in developing nasal spray and intravenous formulations of anti-seizure drugs for rapid administration during repletion seizure episodes. This is encouraging as faster termination of seizures can help reduce emergency room visits and hospitalizations. New product approvals and launches incorporating advanced drug delivery technologies will further fuel the market expansion over the forecast period.

Current Geopolitical Impact on Acute Repetitive Seizures Market Growth

The acute repetitive seizures market is witnessing mixed effects of the ongoing geopolitical conflicts and economic uncertainties. While ongoing tensions between major global economies like US and China is disrupting supply chains for key drug components, the COVID pandemic and war in Ukraine is driving higher demand for anti-seizure therapies. Rising inflation and recession fears in major markets like Europe and North America could potentially dampen expenditure growth on advanced treatments. However, increasing investment in healthcare sectors by governments trying to strengthen economic recovery may offset some of the demand impact. Drug makers will need to closely monitor changes in trade policies and forge alternative partnerships to mitigate supply risks. They also must work on developing affordable treatment options without compromising quality to boost access in geographies with budget constraints. Overall, strategic pricing, timely regulatory approvals and expansions into emerging markets could help sustain long term market prospects despite short term volatility from geopolitical headwinds.